Multiple effects of paclitaxel are modulated by a high c-myc amplification level

Experimental Cell Research

Volumn 290, Issue 1, 2003, Pages 49-59

  Bottone, Maria Grazia ^a   Soldani, Cristiana ^a   Tognon, Gianluca ^b   Gorrini, Chiara ^b   Lazzè, M Claudia ^b   Brison, Olivier ^c   Ciomei, Marina ^d   Pellicciari, Carlo ^a,b   Scovassi, A Ivana ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b CNR   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d PFIZER INC   (United States)

Author keywords

Apoptosis; c myc; Colon carcinoma cells; Paclitaxel; Phosphorylated c Myc

Indexed keywords

MYC PROTEIN; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; GENE AMPLIFICATION; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MULTINUCLEAR CELL; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SERUM;

EID: 0141569222     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(03)00312-4     Document Type: Article

References (64)

1. Kirsch-Volders M., Parry E.M. Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. Mutation Res. 355:1996;103-128.
2. Díaz J.F., Andreu J.M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere reversibility, ligand stoichiometry, and competition . Biochemistry. 32:1993;2747-2755.
3. Blagosklonny M.V., Fojo T. Molecular effects of paclitaxel myths and reality (a critical review) . Int. J. Cancer. 83:1999;151-156.
4. Panvichian R., Orth K., Day M.L., Day K.C., Pilat M.J., Pienta K.J. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation a potential early step in drug resistance . Cancer Res. 58:1998;4667-4672.
5. Chen J.-G., Horwitz S.B. Differential mitotic responses to microtubule-stabilizing and destabilizing drugs. Cancer Res. 62:2002;1935-1938.
6. Snyder J.P., Nettles J.H., Cornett B., Downing K.H., Nogales E. The binding conformation of Taxol in β-tubulin a model based on electron crystallographic density . Proc. Natl. Acad. Sci. USA. 98:2001;5312-5316.
7. Rao S., Orr G.A., Chaudary A.G., Kingston D.G.I., Horwitz S.B. Characterization of the Taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids217-231) of beta-tubulin. J. Biol. Chem. 270:1995;20235-20238.
8. Rao S., He L., Chakravarty S., Ojima I., Orr G.A., Horwitz S.B. Characterization of the Taxol binding site on the microtubule. J. Biol. Chem. 274:1999;37990-37994.
9. Nogales E., Wolf S.G., Downing K.H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature. 391:1998;199-203.
10. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA. 92:1995;4507-4511.
11. Ling Y.-H., Tornos C., Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem. 273:1998;18984-18991.
12. Pucci B., Bellincampi L., Tafani M., Masciullo V., Melino G., Giordano A. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Exp. Cell Res. 252:1999;134-143.
13. Scatena C.D., Stewart Z.A., Mays D., Tang L.J., Keefer C.J., Leach S.D., Pietenpol J.A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J. Biol. Chem. 273:1998; 30777-30784.
14. Rodi D.J., Janes R.W., Sanganee H.J., Holton R.A., Wallace B.A., Makowski L. Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol-binding protein. J. Mol. Biol. 285:1999;197-203.
15. Blagosklonny M.V., Giannakakou P., el-Deiry W.S., Kingston D.G., Higgs P.I., Neckers L., Fojo T. Raf-1/bcl-2 phosphorylation a step from microtubule damage to cell death . Cancer Res. 57:1997;130-135.
16. Torres K., Horwitz S.B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 58:1998;3620-3626.
17. Mabuchi S., Ohmichi M., Kimura A., Hisamoto K., Hayakawa J., Nishio Y., Adachi K., Takahashi K., Arimoto-Ishida E., Nakatsuji Y., Tasaka K., Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J. Biol. Chem. 277:2002;33490-33500.
18. Ito T., Deng X., Carr B., May W.S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 272:1997;11671-11673.
19. Okano J., Rustgi A.K. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J. Biol. Chem. 276:2001;19555-19564.
20. McDaid H.M., Horwitz S.B. Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol. Pharmacol. 60:2001;290-301.
21. Kottke T.J., Blajeski A.L., Meng X.W., Svingen P.A., Ruchaud S., Mesner P.W., Boerner S.A., Samejima K., Henriquez N.V., Chilcote T.J., Lord J., Salmon M., Earnshaw W.C., Kaufmann S.H. Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J. Biol. Chem. 277:2002;804-815.
22. Prendergast G. Mechanisms of apoptosis by c-myc. Oncogene. 18:1999;2967-2987.
23. Donzelli M., Bernardi R., Negri C., Prosperi E., Padovan L., Lavialle C., Brison O., Scovassi A.I. Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene. Oncogene. 18:1999;439-448.
24. G. Gorrini, M. Donzelli, A. Torriglia, R. Supino, O. Brison, R. Bernardi, C. Negri, M. Denegri, M.-F. Counis, G.N. Ranzani, A.I. Scovassi, Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level, Int. J. Mol. Med. 11 (2003) 737-742.
25. Lavialle C., Modjtahedi N., Cassingena R., Brison O. High c-myc amplification level contributes to the tumorigenic phenotype of the human breast carcinoma cell line SW613-S. Oncogene. 3:1998;335-339.
26. Matlashewski G., Banks L., Pin D., Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur. J. Biochem. 154:1986;665-672.
27. Soldani C., Bottone M.G., Biggiogera M., Alpini C., Scovassi A.I., Martin T., Pellicciari C. Nuclear localization of phosphorylated c-Myc protein in human tumor cells. Eur. J. Histochem. 46:2002;377-380.
28. Modjtahedi N., Haddada H., Lamonerie T., Lazar E., Lavialle C., Brison O. TGF-α production correlates with tumorigenicity in clones of the SW613-S human colon carcinoma cell line. Int. J. Cancer. 52:1992;483-490.
29. Downing K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell Dev. Biol. 16:2000;89-111.
30. Nasi S., Ciarapica R., Jucker R., Rosati J., Soucek L. Making decisions through Myc. FEBS Lett. 490:2001;153-162.
31. Lutz W., Leon J., Eilers M. Contribution of Myc to tumorigenesis. Biochim. Biophys. Acta. 1602:2002;61-71.
32. Pelengaris S., Khan M., Evan G. c-Myc more than just a matter of life and death . Nat. Rev. Cancer. 2:2002;764-776.
33. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanisms of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA. 90:1993;9552-9556.
34. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:1996;816-825.
35. Yeung T.K., Germond C., Chen X., Wang Z. The mode of action of taxol apoptosis at low concentration and necrosis at high concentration . Biochem. Biophys. Res. Commun. 263:1999;398-404.
36. Debernardis D., Siré E.G., De Feudis P., Vikhanskaya F., Valenti M., Russo P., Parodi S., D'Incalci M., Broggini M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 57:1997;870-874.
37. Lanni J.S., Lowe S.W., Licitra E.J., Liu J.O., Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA. 94:1997;9679-9683.
38. Vikhanskaya F., Vignati S., Beccaglia P., Ottoboni C., Russo P., D'Incalci M., Broggini M. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp. Cell Res. 241:1998;96-101.
39. Cassinelli G., Supino R., Perego P., Polizzi D., Lanzi C., Pratesi G., Zunino F. A role for loss of P53 function in sensitivity of ovarian carcinoma cells to taxanes. Int. J. Cancer. 92:2001;738-747.
40. Blagosklonny M.V. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 21:2002;6249-6254.
41. Walss C., Kreisberg J.I., Luduena R.F. Presence of the betall isotype of tubulin in the nuclei of cultured mesangial cells from rat kidney. Cell Motil. Cytoskeleton. 42:1999;274-284.
42. Chabin-Brion K., Marceiller J., Perez F., Settegrana C., Drechou A., Durand G., Pous C. The Golgi complex is a microtubule-organizing organelle. Mol. Biol. Cell. 12:2001;2047-2060.
43. Carré M., André N., Carles G., Borghi H., Brichese L., Briand C., Braguer D. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J. Biol. Chem. 277:2002;33664-33669.
44. Yin F., Perez R., Redpath J.L. Paclitaxel exposure time determines the nature of the interaction with radiation in HeLa cells the role of apoptosis . Eur. J. Cancer. 36:2000;1426-1432.
45. Alexandrova N., Niklinski J., Bliskovsky V., Otterson G.A., Blake M., Kaye F.J., Zajac-Kaye M. The N-terminal domain of c-Myc associates with α-tubulin and microtubules in vivo and in vitro. Mol. Cell. Biol. 15:1995;5188-5195.
46. Noguchi K., Kitanaka C., Yamana H., Kokubu A., Mochizuki T., Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J. Biol. Chem. 274:1999;32580-32587.
47. Gregory M.A., Hann S.R. c-Myc proteolysis by the ubiquitin-proteasome pathway stabilization of c-Myc in Burkitt's lymphoma cells . Mol. Cell. Biol. 20:2000;2423-2435.
48. Niklinski J., Claassen G., Meyers C., Gregory M.A., Allegra C.J., Kaye F.J., Hann S.R., Zajac-Kaye M. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma. Mol. Cell. Biol. 20:2000;5276-5284.
49. Flinn E.M., Busch C.M.C., Wright A.P.H. myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol. Cell. Biol. 18:1998;5961-5969.
50. Salghetti S.E., Kim S.Y., Tansey W.P. Destruction of Myc by ubiquitin-mediated proteolysis cancer-associated and transforming mutations stabilize Myc . EMBO J. 18:1999;717-726.
51. Arabi A., Rustum C., Hallberg E., Wright A.P.H. Accumulation of c-Myc and proteasomes at the nucleoli of cells containing elevated c-Myc protein levels. J. Cell. Sci. 116:2003;1707-1717.
52. Bond V.C., Wold B. Nucleolar localization of myc transcripts. Mol. Cell. Biol. 13:1993;3221-3230.
53. Henriksson M., Classon M., Ingvarsson S., Koskinen P., Sumegi J., Klein G., Thyberg J. Elevated expression of c-myc and N-myc produces distinct changes in nuclear fine structure and chromatin organization. Oncogene. 3:1988;587-593.
54. Spector D.L., Watt R.A., Sullivan N.F. The v- and c-myc oncogene proteins colocalize in situ with small nuclear ribonucleoprotein particles. Oncogene. 1:1987;5-12.
55. Roberts J.R., Allison D.C., Donehower R.C., Rowinsky E.K. Development of polyploidization in Taxol-resistant human leukemia cells in vitro. Cancer Res. 50:1990;710-716.
56. 1-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression. Carcinogenesis. 20:1999;1161-1168.
57. Morrish F., Giedt C., Hockenbery D. c-MYC apoptotic function is mediated by NRF-1 target genes. Genes Dev. 17:2003;240-255.
58. 2 phase of the cell cycle. Mol. Cell. Biol. 21:2001;4929-4937.
59. Supino R., Perego P., Gatti L., Caserini C., Leonetti C., Colantuono M., Zuco V., Carenini N., Zupi G., Zunino F. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. Eur. J. Cancer. 37:2001;2247-2256.
60. Tseng C.-J., Wang Y.-J., Liang Y.-C., Jeng J.-H., Lee W.-S., Lin J.-K., Chen C.-H., Liu I.-C., Ho Y.-S. Microtubule damaging agents induce apoptosis in HL60 cells and G2/M cell cycle arrest in HT 29 cells. Toxicology. 175:2002;123-142.
61. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235:2002;179-192.
62. Jagetia G.C., Adiga S.K. Correlation between micronuclei induction and cell survival in V79 cells exposed to paclitaxel (Taxol) in conjunction with radiation. Mutation Res. 377:1997;105-113.
63. Kurdoglu B., Cheong N., Guan J., Corn B.W., Curran W.J., Iliakis G. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin. Cancer Res. 5:1999;2580-2587.
64. Iancu C., Mistry S.J., Arkin S., Atweh G.F. Taxol and anti-stathmin therapy a synergistic combination that targets the mitotic spindle . Cancer Res. 60:2000;3537-3541.